The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.
November 20th 2024
Cindy M. Pabon, MD, highlights key findings and the clinical implications of 3 trials addressing questions in gastric and gastroesophageal cancer.
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
PER LIVER CANCER TUMOR BOARD: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable ...
November 16, 2024
Register Now!
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition
December 6, 2024
Register Now!
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting
View More
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
FDA Grants Breakthrough Designation to Frontline Pembrolizumab/Lenvatinib for HCC
July 23rd 2019The FDA has granted a breakthrough therapy designation to the combination of pembrolizumab and lenvatinib for the first-line treatment of patients with advanced unresectable hepatocellular carcinoma that is not amenable to locoregional therapy.
Dr. Messersmith on the Rise of Molecular Testing in mCRC
July 19th 2019Wells A. Messersmith, MD, co-leader of the Developmental Therapeutics Program, and director, GI Cancer Program, at the University of Colorado School of Medicine, discusses the rise of molecular testing in metastatic colorectal cancer (mCRC).
Dr. El-Khoueiry on Choosing Between Immunotherapy Agents and TKIs in HCC
July 19th 2019Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses choosing between immunotherapy agents and TKIs in hepatocellular carcinoma (HCC).
Regorafenib/Nivolumab Combo to Be Explored in Phase III MSS CRC Trial
July 18th 2019The combination of regorafenib and nivolumab will be compared with regorafenib alone in a phase III trial of patients with microsatellite stable colorectal cancer, following encouraging phase Ib findings of the REGONIVO study.
NTRK Gene Fusions: Finding the "Golden Ticket" in Oncology
July 18th 2019During an OncologyLive Peer Exchange, the panelists discuss some of the challenges they face when conducting molecular testing, including determining which patients to test, when to test, and how to test to ensure that no golden tickets, such as NTRK gene fusions, are missed. They also discuss the data surrounding TRK inhibitors and their experiences using these agents.